Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Jeffrey How Image

      Jeffrey How, MD MPH MS

      Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery

      Meet Jeffrey How, M.D.

      Present Title & Affiliation

      Primary Appointment

      Assistant Professor, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Assistant Professor, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2021The University of Texas M.D. Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas, US, Biochemical Sciences, Master of Science
      2017Harvard University T.H. Chan School of Public Health, Boston, Massachusetts, US, Epidemiology, Master of Public Health
      2014McGill University School of Medicine, Montreal, CA, MD

      Postgraduate Training

      2019-2023Clinical Fellowship, Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
      2017-2017Felix Rutledge Fellowship, Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
      2014-2019Clinical Residency, Obstetrics and Gynecology, McGill University, Montreal

      Licenses & Certifications

      2026American Board of Obstetrics and Gynecology, Gynecologic Oncology
      2024American Board of Obstetrics and Gynecology
      2021Texas Medical License
      2019Royal College of Physicians and Surgeons of Canada, Obstetrics and Gynecology

      Experience & Service

      Intramural Institutional Committee Activities

      Committee Member, Gynecologic Oncology Education Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Core Development Team Lead, Cervical Cancer Clinical Management Algorithm Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Committee Member, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Representative of the Department of Gynecologic Oncology and Reproductive Medicine, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Core Development Team Lead, Endometrial Cancer Clinical Management Algorithm Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Committee Member, Gynecologic Oncology Fellowship Program Admissions Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Committee Member, Gynecologic Oncology Fellowship Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Extramural Institutional Committee Activities

      Clinical Quality Improvement Fellow, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2022 - 2023

      Gynecologic Oncology Fellowship Program Representative, House Staff Senate, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2020 - 2021

      Fellowship Program Education Committee Member, The University of Texas MD Anderson Gynecologic Oncology Fellowship, The University of Texas MD Anderson Cancer Center, 2019 - 2023

      Residency Program Committee, McGill University Obstetrics and Gynecology Residency, The University of Texas MD Anderson Cancer Center, 2018 - 2018

      MORE (OB) Quality Improvement Committee, Royal Victoria Hospital Department of Obstetrics and Gynecology, The University of Texas MD Anderson Cancer Center, 2016 - 2018

      Editorial Activities

      Editorial Board Member, Scientific reports, 2026 - Present

      Honors & Awards

      2026 - PresentNIH/NCI K12 Paul Calabresi Clinical Oncology Award, NCI
      20232023 American Society of Clinical Oncology Annual Meeting Merit Award, Conquer Cancer, the ASCO Foundation
      2023Society of Gynecologic Oncology Bridges Research Initiative Scholar, Society of Gynecologic Oncology
      2022 - 2023Linda Manning Fellowship in Ovarian Cancer Research Award, The University of Texas MD Anderson Cancer Center
      20222022 AACR-Doreen Putrah Cancer Research Foundation Scholar-in-Training Award, Annual Meeting of the American Association for Cancer Research
      2022Recipient of the 2022 Dr. Chien-Tien Hsu Fellow Scholarship in Gynecologic Oncology, Hsu Medical Education Foundation
      2021Second place in the Oral Competition for Clinical Research, The University of Texas MD Anderson Cancer Center Trainee Research Day 2021
      2021Thomas H. and Mayme P. Scott Fellowship in Cancer Research, The University of Texas MD Anderson Cancer Center Trainee Research Day 2021
      2020 - 2021The University of Texas MD Anderson Gynecologic Oncology Fellowship Program Service Award, The University of Texas MD Anderson Cancer Center
      2020Immunology Program First-author Review Incentive Award, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
      2020Dr. Henry R. Shibata Fellowship Award, Cedars Cancer Foundation
      2018 - 2019Erin and Jane Molson Award for Excellence in Research for the academic year 2018 – 2019, McGill University Department of Obstetrics and Gynecology
      2017Award for best oral presentation for residents and fellows, 51st annual meeting of the Association of Obstetricians and Gynecologists of Quebec
      2017Brian Newton Memorial Prize for Excellence in Gynecologic Oncology for the academic year 2016 – 2017, McGill University Department of Obstetrics and Gynecology
      2016 - 2017Award for Professionalism in Obstetrics and Gynecology for the academic year 2016 – 2017, Jewish General Hospital Department of Obstetrics and Gynecology
      2016 - 2017Harvard School of Public Health Grant for studies for the academic year 2016 – 2017, Harvard School of Public Health
      2016Selected to represent McGill University for “best of the best resident research presentations”, 2016 Annual Meeting of the Association of Academic Professionals of Obstetrics and Gynecology of Canada
      2015 - 2016Award for Professionalism in Obstetrics and Gynecology for the academic year 2015 – 2016, St. Mary’s Hospital Department of Obstetrics and Gynecology
      2015 - 2016Harvard School of Public Health Grant for studies for the academic year 2015 – 2016, Harvard School of Public Health
      2014Recipient of travel grant to the Shingo Fujii Young Doctors’ Summit at the 15th biennial meeting of the International Gynecologic Cancer Society, 15th biennial meeting of the International Gynecologic Cancer Society
      2012Award for Best Scientific Oral Presentation, Young Doctors’ summit of the 14th biennial meeting of the International Gynecologic Cancer Society
      2011Recipient of the Fonds de la recherche en santé du Québec Summer Research Bursary
      2009Yale Book Award for outstanding personal character and promise of intellectual achievement, Yale Club of Montreal

      Professional Memberships

      European Society for Medical Oncology

      2024 - Present

      NRG Oncology

      2023 - Present

      American Association for Cancer Research

      2020 - Present

      Society for Immunotherapy of Cancer

      2020 - Present

      International Gynecologic Cancer Society

      2019 - Present

      American Society of Clinical Oncology

      2019 - Present

      Society of Gynecologic Oncology

      2019 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2024. Exciting New Clinical Trials to Watch Out for in 2024. Invited. Gynecologic Oncology and Reproductive Medicine Grand Rounds. Houston, Texas, US.
      2. 2022. From Bedside to Bench and Back: Deciphering the Tumor Microenvironment to unravel mechanisms of Immunotherapy Resistance in Endometrial Cancer. Invited. Gynecologic Oncology and Reproductive Medicine Grand Rounds. Houston, Texas, US.
      3. 2018. Risk factors for synchronous primary ovarian and endometrial cancer in a population-based sample. Conference. McGill University Department of Obstetrics & Gynecology Research Day. Montreal, Quebec, CA.
      4. 2017. Survival outcomes of sentinel lymph node mapping in high-risk endometrial histologies. Conference. McGill University Department of Obstetrics & Gynecology Research Day. Montreal, Quebec, CA.

      Regional Presentations

      1. 2026. MD Anderson Gyn Onc Rare Tumor Program. Invited. Western Association of Gynecologic Oncologists. Napa, California, US.

      National Presentations

      1. 2026. Multidisciplinary Case Panel in Gynecologic Cancers. Panelist. MD Anderson Cancer Network Gynecology Integration Retreat. Houston, Texas, US.
      2. 2025. Management of advanced mismatch repair proficient endometrial cancer (to give or not to give immunotherapy). Invited. MD Anderson Cancer Network Gynecology Integration Retreat. Houston, Texas, US.
      3. 2024. Minimally-invasive vs open radical hysterectomy for early-stage cervical cancer. Invited. 72nd Annual Meeting of the Society of Pelvic Surgeons. Houston, Texas, US.
      4. 2024. Management of Immunotherapy toxicities. Invited. 2024 Annual Meeting of the Felix Rutledge Society. Fort Lauderdale, Florida, US.
      5. 2016. The impact of the sentinel lymph node mapping in the management of pre-operative grade 1 endometrial cancer. Conference. Association of Academic Professionals in Obstetrics and Gynecology of Canada Annual Meeting. Toronto, Ontario, CA.

      International Presentations

      1. 2025. Phase II trial of immune checkpoint blockade with or without ELI-002 7P for the treatment of recurrent KRAS-mutated endometrial and ovarian cancer. Invited. 2025 Gynecologic Mesonephric-like Adenocarcinoma Consortium Meeting. Houston, US.
      2. 2024. Novel KRAS vaccines. Invited. 2024 Gynecologic Mesonephric-like adenocarcinoma Consortium Meeting. Houston, US.
      3. 2022. Immunotherapy in Gynecologic Cancer: A New Era of Cancer Therapy. Invited. Department of Obstetrics and Gynecology Grand Rounds. Montreal, CA.
      4. 2022. Sentinel Lymph Node Mapping in Endometrial Cancer. Invited. 2022 Annual Conference of the West Lake Summit of International Gynecological Oncology & Zhejiang Gynecologic Cancer Society (Virtual), CN.
      5. 2021. Immunotherapy in Gynecologic Cancer: A New Era of Cancer Therapy. Invited. Department of Obstetrics and Gynecology Grand Rounds. Montreal, CA.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - Present
      Title:Paul Calabresi Clinical Oncology Award
      Funding Source:NCI
      Role:PI
      ID:K12CA088084
      Date: 2025 - Present
      Title:Start-up funds
      Funding Source:The University of Texas MD Anderson Cancer Center
      Role:PI

      Selected Publications

      Peer-Reviewed Articles

      1. Bou Zerdan M, Saab R, Meyer LA, Munsell MF, How JA, Soliman PT. Demographics, clinicopathological features, and survival outcomes of women with endometrial neuroendocrine tumors. Gynecol Oncol 207:34-39, 2026. e-Pub 2026. PMID: 41785530.
      2. Derbala, M, Hajjar, J, Stephen, B, Gurses, S, Kwiatkowski, E, Budde, P, Zucht, HD, Bräutigam, M, Lindemann, AS, Abhari, BA, Gouda, M, Castillo, L, Zarifa, A, How, JA, Rodriguez, E, Moyers, JT, Hong, DS, Fu, S, Meric-Bernstam, F, Naing, A. Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors. ESMO Open 10(8), 2025. e-Pub 2025. PMID: 40768895.
      3. Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio IC, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh C, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Solis Soto LM, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA. Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities. Clin Cancer Res 31(19):4122-4135, 2025. PMID: 40748258.
      4. Nardo M, Xavier CB, Stephen B, How JA, Moyers J, Subbiah V, Hong DS, Naing A. Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial. J Immunother Precis Oncol 10(8):143-151, 2025. e-Pub 2025. PMID: 40212844.
      5. Alhalabi O, Gouda MA, Milton DR, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Tannir NM, Naing A. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma. Cancer Med 14(4)(4), 2025. e-Pub 2025. PMID: 39945382.
      6. Brodsky AL, Legarreta AF, How JA, Vuttaradhi V, Sood AK, Ramondetta LM, Gershenson DM, Hillman RT. Survival outcomes comparing minimally invasive versus open cytoreductive surgery in recurrent adult-type granulosa cell tumors. Am J Obstet Gynecol 233(1):51.e1-51.e10, 2025. e-Pub 2025. PMID: 39824329.
      7. Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. J Immunother Precis Oncol 7(4):247-254, 2024. e-Pub 2024. PMID: 39524469.
      8. Brodsky AL, Legarreta AF, Fellman BM, Glassman D, How J, Vuttaradhi V, Sood AK, Ramondetta LM, Gershenson D, Hillman RT. TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors. Int J Gynecol Cancer 35(8), 2024. e-Pub 2024. PMID: 39395821.
      9. How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Phase II trial of pembrolizumab in combination with chemotherapy for frontline treatment of advanced epithelial ovarian cancer. Med 6(1), 2024. e-Pub 2024. PMID: 39151421.
      10. How, JA, Legarreta, AF, Handley, KF, Fellman, B, Foster, KI, Glassman, D, Vuttaradhi, VK, Brodsky, AL, Lawson, BC, Frumovitz, M, Westin, SN, Ramondetta, LM, Gershenson, DM, Sood, AK, Hillman, RT. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. American journal of obstetrics and gynecology 230(5):544.e1-544.e13, 2024. e-Pub 2024. PMID: 38191019.
      11. Bernard, L, How, JA, Patel, S, Yates, MS, Jazaeri, AA. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab. Gynecologic oncology 180:139-145, 2024. e-Pub 2024. PMID: 38091773.
      12. Foster KI, Flores Legarreta A, Kamat R, Handley KF, Glassman D, How JA, Lawson BC, Westin SN, Ramondetta LM, Frumovitz M, Gershenson DM, Sood AK, Hillman RT. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol 228(6):724.e1-724.e9, 2023. e-Pub 2023. PMID: 36907533.
      13. Batman S, Rauh-Hain JA, Grinsfelder MO, Harrison R, Avila M, Cun H, How JA, Tandon N, Wang X, Hinchcliff E, Jazaeri AA, Schmeler KM. Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report. Case Rep Oncol 16(1):273-278, 2023. e-Pub 2023. PMID: 37123608.
      14. How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35954359.
      15. Marchocki Z, Cusimano MC, Clarfield L, Kim SR, Fazelzad R, Espin-Garcia O, Bouchard-Fortier G, Rossi EC, Stewart KI, Soliman PT, How JA, Gotlieb WH, Holloway RW, Ianieri MM, Cabrera S, Lim YK, Ferguson SE. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol 225(4):367.e1-367.e39, 2021. e-Pub 2021. PMID: 34058168.
      16. How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol 162(1):24-31, 2021. e-Pub 2021. PMID: 33958211.
      17. Turkdogan S, Schnitman G, Wang T, Gotlieb R, How J, Gotlieb WH. Development of a Digital Patient Education Tool for Patients With Cancer During the COVID-19 Pandemic. JMIR Cancer 7(2):e23637, 2021. e-Pub 2021. PMID: 34101611.
      18. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs 39(3):829-835, 2021. e-Pub 2021. PMID: 33415580.
      19. How JA, Siedel JH, Shafer A. Post-operative gastroparesis following carbohydrate loading in a diabetic patient. Gynecol Oncol Rep 36:100714, 2021. e-Pub 2021. PMID: 33644283.
      20. How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel) 13(5):1-18, 2021. e-Pub 2021. PMID: 33668244.
      21. How JA, Jazaeri AA, Soliman PT, Fleming ND, Gong J, Piha-Paul SA, Janku F, Stephen B, Naing A. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep 11(1):3667, 2021. e-Pub 2021. PMID: 33574401.
      22. Kogan L, Matanes E, Wissing M, Mitric C, How J, Amajoud Z, Abitbol J, Yasmeen A, López-Ozuna V, Eisenberg N, Lau S, Salvador S, Gotlieb WH. The added value of sentinel node mapping in endometrial cancer. Gynecol Oncol 158(1):84-91, 2020. e-Pub 2020. PMID: 32349874.
      23. Abitbol J, Gotlieb W, Zeng Z, Ramanakumar A, Kessous R, Kogan L, Pare-Miron V, Rombaldi M, Salvador S, Kucukyazici B, Brin S, How J, Lau S. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy. Int J Gynecol Cancer 29(9):1341-1347, 2019. e-Pub 2019. PMID: 31601648.
      24. Wissing M, Mitric C, Amajoud Z, Abitbol J, Yasmeen A, López-Ozuna V, How J, Kessous R, Eisenberg N, Lau S, Salvador S, Gotlieb WH, Kogan L. Risk factors for lymph nodes involvement in obese women with endometrial carcinomas. Gynecol Oncol 155(1):27-33, 2019. e-Pub 2019. PMID: 31349997.
      25. 17Abitbol J, Lau S, Salvador S, How J, Kogan L, Kessous R, Brin S, Drummond N, Ramanakumar AV, Gotlieb R, Tatar A, Gomolin A, Gotlieb WH. A three-pronged approach to evaluating robotic surgery. Gynecol Pelvic Med:2(15):1 - 12, 2019. e-Pub 2019.
      26. Kessous R, How J, Abitbol J, Puzhakkal S, Kogan L, Yasmeen A, Salvador S, Gotlieb WH, Lau S. Triple tracer (blue dye, indocyanine green, and Tc99) compared to double tracer (indocyanine green and Tc99) for sentinel lymph node detection in endometrial cancer: a prospective study with random assignment. Int J Gynecol Cancer 29(7):1121-1125, 2019. e-Pub 2019. PMID: 31320490.
      27. Gotlieb R, Abitbol J, How JA, Ben-Brith I, Abenhaim HA, Lau SK, Basik M, Rosberger Z, Geva N, Gotlieb WH, Mintz A. Gender differences in how physicians access and process information. Gynecol Oncol Rep 27:50-53, 2019. e-Pub 2019. PMID: 30662932.
      28. Nguyen DB, How J, Ziegler C, Madar J. Acute Respiratory Distress Syndrome After Uterine Artery Embolization. Obstet Gynecol 132(4):956-959, 2018. e-Pub 2018. PMID: 30204705.
      29. Bougie O, Zuckerman SL, Switzer N, How J, Sey M. Influence of Resident Involvement in Obstetrics and Gynaecology Surgery on Surgical Outcomes: Systematic Review and Meta-Analysis. J Obstet Gynaecol Can 40(9):1170-1177, 2018. e-Pub 2018. PMID: 30007802.
      30. How JA, O'Farrell P, Amajoud Z, Lau S, Salvador S, How E, Gotlieb WH. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Minerva Ginecol 70(2):194-214, 2018. e-Pub 2018. PMID: 29185673.
      31. How J, Boldeanu I, Lau S, Salvador S, How E, Gotlieb R, Abitbol J, Halder A, Amajoud Z, Probst S, Brin S, Gotlieb W. Unexpected locations of sentinel lymph nodes in endometrial cancer. Gynecol Oncol 147(1):18-23, 2017. e-Pub 2017. PMID: 28716308.
      32. How J, Gauthier C, Abitbol J, Lau S, Salvador S, Gotlieb R, Pelmus M, Ferenczy A, Probst S, Brin S, Fatnassi A, Gotlieb W. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. Gynecol Oncol 144(3):503-509, 2017. e-Pub 2017. PMID: 28104296.
      33. How J, Gotlieb WH, Press JZ, Abitbol J, Pelmus M, Ferenczy A, Probst S, Gotlieb R, Brin S, Lau S. Comparing indocyanine green, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. Gynecol Oncol 137(3):436-42, 2015. e-Pub 2015. PMID: 25870917.
      34. Zeng XZ, Lavoue V, Lau S, Press JZ, Abitbol J, Gotlieb R, How J, Wang Y, Gotlieb WH. Outcome of robotic surgery for endometrial cancer as a function of patient age. Int J Gynecol Cancer 25(4):637-44, 2015. e-Pub 2015. PMID: 25723778.
      35. How JA, Abitbol J, Lau S, Gotlieb WH, Abenhaim HA. The impact of qualitative research on gynaecologic oncology guidelines. J Obstet Gynaecol Can 37(2):138-144, 2015. e-Pub 2015. PMID: 25767946.
      36. Lau S, Aubin S, Rosberger Z, Gourdji I, How J, Gotlieb R, Drummond N, Eniu I, Abitbol J, Gotlieb W. Health-related quality of life following robotic surgery: a pilot study. J Obstet Gynaecol Can 36(12):1071-1078, 2014. e-Pub 2014. PMID: 25668042.
      37. Abitbol J, Lau S, Ramanakumar AV, Press JZ, Drummond N, Rosberger Z, Aubin S, Gotlieb R, How J, Gotlieb WH. Prospective quality of life outcomes following robotic surgery in gynecologic oncology. Gynecol Oncol 134(1):144-9, 2014. e-Pub 2014. PMID: 24796633.
      38. Lavoue V, Zeng X, Lau S, Press JZ, Abitbol J, Gotlieb R, How J, Wang Y, Gotlieb WH. Impact of robotics on the outcome of elderly patients with endometrial cancer. Gynecol Oncol 133(3):556-62, 2014. e-Pub 2014. PMID: 24708920.
      39. Drudi L, Press JZ, Lau S, Gotlieb R, How J, Eniu I, Drummond N, Brin S, Deland C, Gotlieb WH. Vaginal vault dehiscence after robotic hysterectomy for gynecologic cancers: search for risk factors and literature review. Int J Gynecol Cancer 23(5):943-50, 2013. e-Pub 2013. PMID: 23669442.
      40. How J, Lau S, Press J, Ferenczy A, Pelmus M, Stern J, Probst S, Brin S, Drummond N, Gotlieb W. Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: a prospective study. Gynecol Oncol 127(2):332-7, 2012. e-Pub 2012. PMID: 22910695.
      41. Halliday D, Lau S, Vaknin Z, Deland C, Levental M, McNamara E, Gotlieb R, Kaufer R, How J, Cohen E, Gotlieb WH. Robotic radical hysterectomy: comparison of outcomes and cost. J Robot Surg 4(4):211-6, 2010. e-Pub 2010. PMID: 27627947.
      42. How JA, Westin SN, Pham M, Lawson B, Chen M, Tandon N, Yuan Y, Zhang R, Jazaeri AA, Sood AK, Grinsfelder MO, Schmeler KM, Vining DJ, Fix SM, Dai Y, Bowen MB, Lu KH, Yates MS, Broaddus R, Soliman PT. Phase II randomized controlled trial of everolimus and letrozole with or without ribociclib in advanced/recurrent endometrial cancer. Nature Communications.

      Review Articles

      1. Mills AM, Euscher ED, McCluggage W, Mirkovic J, Park KJ, Kolin DL, Hoang L, Kim H, How JA, Lu KH, Ring KL, Howitt BE. Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium. Int J Gynecol Pathol, 2026. e-Pub 2026. PMID: 41289365.
      2. Reddy RA, Wilke RN, Soliman PT, Westin SN, How JA. Fertility-Sparing Practices in Uterine Malignancies: A Literature Review. J Gynecol Surg. e-Pub 2025.
      3. Ring, K, Mills, AM, Howitt, BE, Grisham, RN, Euscher, ED, Kim, HS, Klopp, AH, Kolin, DL, McCluggage, WG, Mirkovic, J, Park, K, Aoun, E, Awujo, C, Son, J, Mok, S, Ferri-Borgogno, S, Hong, DS, Hoang, L, Jazaeri, AA, How, JA, Lu, KH. Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics. Gynecologic oncology 197:57-65, 2025. e-Pub 2025. PMID: 40279981.
      4. How JA, Jazaeri AA, Westin SN, Lawson BC, Klopp AH, Soliman PT, Lu KH. Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol 21(11):781-800, 2024. e-Pub 2024. PMID: 39198622.
      5. Fleming, N, Wolfe, CA, Keating, MF, Sans, M, Rangel, KM, Sunny, C, Westin, SN, Jazaeri, AA, Soliman, PT, Taylor, JS, Hillman, RT, How, JA, Lawson, BC, Sood, AK, Eberlin, LS. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery. Journal of Clinical Oncology 42:5573, 2024. e-Pub 2024.
      6. How JA, Frumovitz M, Stewart KI, Soliman PT. Lymphatic Mapping and Sentinel Node Biopsy in High-Grade Uterine Cancers. Curr Oncol Rep 24(11):1521-1529, 2022. e-Pub 2022. PMID: 35781863.
      7. Schnitman G, Wang T, Kundu S, Turkdogan S, Gotlieb R, How J, Gotlieb W. The role of digital patient education in maternal health: A systematic review. Patient Educ Couns 105(3):586-593, 2022. e-Pub 2022. PMID: 34183217.

      Other Articles

      1. How JA, Jazaeri AA Photodynamic therapy: an alternative technique to cervical conization for cervical dysplasia. Med 6(12), 2025. PMID: 41389709.
      2. How JA, Jazaeri AA Integrating CTLA-4/PD-1 blockade into cervical cancer management: Results of COMPASSION-16. Med 6(1):100558, 2025. PMID: 39798550.
      3. How, JA, Jazaeri, AA Immunotherapy in locally advanced cervical cancer. Med 5(6):487-489, 2024. PMID: 38878765.

      Abstracts

      1. How JA, Bou Zerdan M, Melissa, Pham M, Celestino N, Xu X, Scalise CB, Dwivedi B, ElNaggar AC, Liu MC, Westin SN, Jazaeri AA, Soliman PT. Circulating tumor DNA as a prognostic marker in patients with high-risk endometrial cancer. 2025 Annual Global Meeting of the International Gynecologic Cancer Society.
      2. How JA, Abitbol J, Lau S, Gotlieb WH, Abenhaim HA. The Impact of Qualitative Research on Gynecologic Oncology Guidelines. Annual Clinical and Scientific Meeting of the Society of Obstetricians and Gynecologists of Canada.
      3. How JA, Gotlieb W, Press J, Abitbol J, Pelmus M, Ferenczy A, Probst S, Stern J, Gotlieb R, Brin S, Lau S. Sentinel lymph node detection comparing intra-operative cervical injection of indocyanine green, technetium, and blue dye for endometrial cancer. International Gynecologic Cancer Society Global Meeting.
      4. How JA, Boldeanu I, Abitbol J, Lau S, Salvador S, Gotlieb R, Gotlieb W. Unexpected areas of sentinel lymph node detection following intra-operative cervical injection in endometrial cancer. Annual Meeting on Women's Cancer.
      5. How JA, Gauthier C, Abitbol J, Lau S, Salvador S, Gotlieb R, Gotlieb W. Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. Annual Meeting on Women's Cancer.
      6. How JA, Boldeanu I, Abitbol J, Lau S, Salvador S, Gotlieb R, Gotlieb W. Outcomes of patients with pre-operative grade 1 endometrial cancer and sentinel lymph node mapping. Annual Meeting on Women's Cancer.
      7. How JA, Boldeanu I, Lau S, Salvador S, How E, Gotlieb R, Abitbol J, Gotlieb W. Mapping des ganglions sentinelles et cancer de l’endomètre: la valeur de l’injection intra-cervicale. 51st annual meeting of the Association of Obstetricians and Gynecologists of Quebec.
      8. Bougie O, Zuckerman S, Switzer N, How J, Sey M. Influence of Resident Involvement in Obstetrics and Gynecology Surgery on Surgical Outcomes: Systematic Review and Meta-Analysis. Annual Clinical and Scientific Meeting of the Society of Obstetricians and Gynecologists of Canada.
      9. How JA, Abitbol J, Lau S, Salvador S, Gotlieb R, Gotlieb W. Survival Outcomes of patients with high-grade endometrial cancer undergoing sentinel lymph node mapping. Annual Meeting on Women's Cancer.
      10. How JA, Gotlieb R, Turkdogan S, Gotlieb WH. The Use of a Multilingual Animated Pregnancy Guide as an adjunct in prenatal care. Annual Clinical and Scientific Meeting of the Society of Obstetricians and Gynecologists of Canada.
      11. How JA, Timms K, Jazaeri A, Lu K, Yates MS. Characterization of homologous recombination deficiency in uncommon epithelial ovarian cancer subtypes. Annual Meeting on Women's Cancer (virtual).
      12. How JA, Jazaeri A, Fu S, Rodon Ahnert J, Gong J, Meric-Bernstam F, Naing A. Characteristics and clinical outcomes of patients with recurrent microsatellite stable endometrial cancer undergoing early phase immunotherapy clinical trials. International Gynecologic Cancer Society Annual Global Meeting (virtual).
      13. How JA, Dang M, Euscher E, Yates M, Peng W, Patel S, Lu K, Hwu P, Wang L, Jazaeri A. The impact of the tumor immune microenvironment on response to pembrolizumab in patients with microsatellite instability-high endometrial cancer. American Association for Cancer Research Virtual Special Conference: Endometrial Cancer: New Biology driving research and treatment (virtual).
      14. How JA, Dang M, Euscher E, Yates M, Peng W, Patel S, Lu K, Hwu P, Wang L, Jazaeri A. The tumor immune microenvironment shapes response to pembrolizumab in microsatellite instability-high endometrial cancer. Annual Meeting on Women's Cancer.
      15. How JA, Patel S, Fellman B, Lu K, Ramondetta L, Westin SN, Fleming N, Soliman PT, Jazaeri AA. The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: an examination of toxicity and treatment efficacy in clinical practice. Annual Meeting on Women's Cancer (virtual).
      16. How JA, Fellman B, Westin SN, Sood AK, Fleming ND, Yuan Y, Shafer A, Zand B, Schmeler KM, Nick A, Lu KH, Coleman R, Jazaeri AA. The feasibility and efficacy of pembrolizumab in combination with chemotherapy in patients undergoing frontline treatment of ovarian cancer. International Gynecologic Cancer Society Annual Global Meeting (virtual).
      17. How JA, Dang M, Ferri-Borgogno S, Euscher E, Yates M, Peng W, Patel S, Burks JJ, Vletic I, Gomez J, Lu K, Mok SC, Wang L, Jazaeri A. Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancer. AACR Annual Meeting.
      18. How JA, Flores Legarreta A, Fellman B, Handley KF, Foster KI, Glassman D, Lawson B, Ramondetta LM, Gershenson DM, Sood AK, Hillman RF. Impact of cytoreductive surgery on survival outcomes for recurrent adult-type granulosa cell tumors of the ovary. Annual Meeting of the American Society of Clinical Oncology.
      19. How JA, Westin S, Sims T, Lito K, Celestino J, Rangel KM, Peng W, Wang L, Jazaeri AA. Trial in progress - Uncovering Mechanisms of Response of Pembrolizumab and Lenvatinib for the Treatment of Platinum resistant High grade Serous Ovarian Cancer. Annual Meeting of the American Society of Clinical Oncology.
      20. How JA, Rauh-Hain JA, Grinsfelder M, Rangel KM, Roder S, Shafer A, Schmeler K, Boruta D, Fleming ND, Lu KH, Vining DJ, Frumovitz M, Jazaeri AA. Trial in progress - Triage of advanced cervical cancer through immunotherapy induction (TRACTION). Annual Meeting of the American Society of Clinical Oncology.
      21. Aoun E, Euscher E, Awujo C, Lawson B, Jazaeri A, Lu K, How JA. Clinicopathologic features of mesonephric-like adenocarcinoma of the ovary and peritoneum. Annual Meeting on Women's Cancer.
      22. Clark HD, Lito K, Fellman B, Fix SM, Knisely A, Fleming ND, Shafer A, Sims T, Soliman PT, Taylor J, Westin SN, Jazaeri AA, How JA. Efficacy pembrolizumab and lenvatinib monotherapy and combination therapy in patients with platinum-resistant high-grade serous ovarian cancer. Annual Meeting on Women's Cancer.
      23. How JA, Westin SN, Pham M, Lawson B, Chen M, Fellman B, Yuan Y, Jazaeri AA, Grinsfelder MO, Schmeler K, Lu KH, Yates MS, Broaddus R, Soliman PT. Phase II randomized controlled trial of everolimus and letrozole with or without ribociclib in advanced/recurrent endometrial cancer. 2025 Annual Global Meeting of the International Gynecologic Cancer Society.

      Book Chapters

      1. How JA, Abitbol J, Gotlieb WH. Minimally invasive surgery in ovarian cancer. In: Surgery for ovarian cancer. 4th. CRC Press, 2023.
      2. How JA, Patel A, Jazaeri AA. Immuno-oncology for Gynecologic Malignancies. In: Immunotherapy. 4th. Springer Nature, 193-232, 2022.
      3. How J, Patel A, Jazaeri A. Immuno-oncology for Gynecologic Malignancies. In: Immunotherapy. 3rd. Springer Nature, 2020.
      4. How J, Gotlieb WH. Sentinel lymph node evaluation in endometrial cancer. In: Uterine Cancer: Diagnosis & Management, 2014.
      5. Bou Zerdan M, How JA, Soliman PT. Neoplastic Diseases of the Uterus. In: Comprehensive Gynecology. 9th. Elsevier.
      6. How JA, Grinsfelder MO, Westin SN. Tumors of the Uterine Corpus. In: MD Anderson Manual of Medical Oncology. 5th. McGraw Hill / Medical.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top